The Future of Ocular Gene Editing is Here at SMi’s Ophthalmic Drugs 2018
London, United Kingdom, August 31, 2018 --(PR.com)-- SMi Group are delighted to welcome the expertise from a senior panel of big pharma and ophthalmic organisations, as well as regulatory bodies, at the 2nd annual Ophthalmic Drugs 2018 conference, taking place in November in the City of London, UK.
Outstanding speaker line-up for 2018:
The event will address the impact of the overwhelming digitalisation such as artificial intelligence in drug discovery and how companies, from biotech's to pharma, need to adapt. It will also explore the future of ocular gene editing and a regulatory perspective of the industry. Hear from opinion leaders such as Roche, Santen, Aerie Pharmaceuticals, MHRA, Nightstar Therapeutics and more.
Featured Highlights:
- Discover recent advances in the treatment of glaucoma
- Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy
- Discuss case studies on novel non-invasive and site-specific drug delivery strategies
- Examine the applications of artificial intelligence in drug discovery
- Explore the use of biomarkers and surrogate end-points from a regulatory perspective
Snapshot of last year’s attendees:
Advanced Imaging Specialist | CBO | CEO | Chief Medical Officer | Clinical Development Scientist | Co-Founder, Chief Innovation Officer | CSO/CMO | CTO | Global Clinical Leader | Pharmaceutical Assessor | R&D Director | RSM Ophthalmology | Senior Clinical Director, Ophthalmology | Senior Director, Clinical Research & Development | Senior Manager, Early Development Group | Senior Vice President, Development | Sr Director Pharmaceutical Sciences | Translational Research Manager | Vice President, Therapeutical Area Head of Ophthalmology | VP, Medical Director, UK and Head of Medical Affairs EU...and more
Check out last year's full attendee list in the download centre online.
For those looking to attend, there is currently a £200 early-bird saving, ending August 31st.
Download the 2018 agenda online and see the full speaker line-up and presentations, as well as the attendee list from last year at: www.ophthalmicdrugs.com/prc
SMi Presents the 2nd Annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.ophthalmicdrugs.com/prc
Sponsors: Experimentica | Nemera
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Outstanding speaker line-up for 2018:
The event will address the impact of the overwhelming digitalisation such as artificial intelligence in drug discovery and how companies, from biotech's to pharma, need to adapt. It will also explore the future of ocular gene editing and a regulatory perspective of the industry. Hear from opinion leaders such as Roche, Santen, Aerie Pharmaceuticals, MHRA, Nightstar Therapeutics and more.
Featured Highlights:
- Discover recent advances in the treatment of glaucoma
- Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy
- Discuss case studies on novel non-invasive and site-specific drug delivery strategies
- Examine the applications of artificial intelligence in drug discovery
- Explore the use of biomarkers and surrogate end-points from a regulatory perspective
Snapshot of last year’s attendees:
Advanced Imaging Specialist | CBO | CEO | Chief Medical Officer | Clinical Development Scientist | Co-Founder, Chief Innovation Officer | CSO/CMO | CTO | Global Clinical Leader | Pharmaceutical Assessor | R&D Director | RSM Ophthalmology | Senior Clinical Director, Ophthalmology | Senior Director, Clinical Research & Development | Senior Manager, Early Development Group | Senior Vice President, Development | Sr Director Pharmaceutical Sciences | Translational Research Manager | Vice President, Therapeutical Area Head of Ophthalmology | VP, Medical Director, UK and Head of Medical Affairs EU...and more
Check out last year's full attendee list in the download centre online.
For those looking to attend, there is currently a £200 early-bird saving, ending August 31st.
Download the 2018 agenda online and see the full speaker line-up and presentations, as well as the attendee list from last year at: www.ophthalmicdrugs.com/prc
SMi Presents the 2nd Annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.ophthalmicdrugs.com/prc
Sponsors: Experimentica | Nemera
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Pav Solanki
02078276138
http://www.ophthalmicdrugs.com/prc
Pav Solanki
02078276138
http://www.ophthalmicdrugs.com/prc
Contact
Categories